US FDA unit CDER develops strategic science and research agenda
A US Food and Drug Administration report from its Center for Drug Evaluation and Research (CDER), made available yesterday in the Federal Register, identifies the current regulatory science needs that will guide the CDER’s strategic planning of internal research initiatives and contributions to the development of agency regulatory science efforts.
“Communicating our science and research needs represents an important step in stimulating research and fostering collaborations with our external partners,” said CDER Director Janet Woodcock, adding: “We look forward to hearing from and working with our stakeholders.”
The report, titled Identifying CDER’s Science and Research Needs Report, identifies the following categories of science and research needs, as follows:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze